CRISPR Therapeutics AG
CRSP
$56.09
-$0.17-0.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 1.86B | 1.90B | 1.94B | 2.00B | 2.11B |
| Total Receivables | -- | 27.10M | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 8.83M | 6.21M | 8.25M | 8.79M | 11.50M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 3.50M | -- | -- | -- | -- |
| Total Current Assets | 1.87B | 1.94B | 1.94B | 2.01B | 2.12B |
|
|
|||||
| Total Current Assets | 1.87B | 1.94B | 1.94B | 2.01B | 2.12B |
| Net Property, Plant & Equipment | 269.70M | 277.55M | 284.83M | 291.57M | 298.51M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | 2.00K |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 28.79M | 27.35M | 27.41M | 26.66M | 20.88M |
| Total Assets | 2.17B | 2.24B | 2.26B | 2.34B | 2.44B |
|
|
|||||
| Total Accounts Payable | 13.06M | 14.71M | 15.58M | 9.45M | 16.46M |
| Total Accrued Expenses | 28.29M | 39.41M | 35.55M | 39.05M | 103.70M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 17.51M | 17.29M | 16.88M | 16.45M | 15.99M |
| Total Finance Division Other Current Liabilities | 60.59M | 16.38M | 21.80M | 62.87M | 69.37M |
| Total Other Current Liabilities | 60.59M | 16.38M | 21.80M | 62.87M | 69.37M |
| Total Current Liabilities | 119.45M | 87.78M | 89.81M | 127.82M | 118.99M |
|
|
|||||
| Total Current Liabilities | 119.45M | 87.78M | 89.81M | 127.82M | 118.99M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 201.85M | 206.41M | 210.66M | 214.85M | 218.94M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 15.64M | 15.77M | 16.00M | 16.23M | 17.16M |
| Total Liabilities | 336.94M | 309.95M | 316.47M | 358.90M | 355.08M |
|
|
|||||
| Common Stock & APIC | 3.33B | 3.30B | 3.26B | 3.23B | 3.20B |
| Retained Earnings | -1.50B | -1.37B | -1.33B | -1.24B | -1.12B |
| Treasury Stock & Other | 4.07M | 1.78M | 10.50M | -2.94M | -1.61M |
| Total Common Equity | 1.83B | 1.93B | 1.94B | 1.98B | 2.08B |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 1.83B | 1.93B | 1.94B | 1.98B | 2.08B |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 1.83B | 1.93B | 1.94B | 1.98B | 2.08B |
|
|
|||||